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Abstract: BACKGROUND: Several multinational controlled clinical trials have shown that triple ther-
apy immunosuppressive regimens which include mycophenolate mofetil (MMF), cyclosporin A (CSA)
and steroids (S) are superior compared with conventional regimens which include azathioprine (AZA),
CSA and S, mainly because MMF reduces the rate of acute rejection episodes in the first 6 months after
kidney transplantation. Post-marketing studies are useful to evaluate the general applicability and costs
of MMF-based immunosuppressive regimens. METHODS: Based on the excellent results of the pub-
lished controlled clinical trials, we have changed the standard triple therapy immunosuppressive protocol
(AZA+CSA+S) to an MMF-based regimen (MMF+CSA+S) at our centre. To analyse the impact of this
change in regimen, we have monitored 6-month patient and graft survival, rejection rate, serum creatinine
and CSA levels, as well as the costs of the immunosuppressive and anti-rejection treatments, in 40 consec-
utive renal transplant recipients (MMF group) and have compared the data with 40 consecutive patients
transplanted immediately prior to the change in regimen (AZA group). RESULTS: Recipient and donor
characteristics were similar in the AZA and MMF groups. Patient survival (37/40; 92.5% in the AZA
group vs 38/40; 95% in the MMF group), graft survival (36/40 vs 36/40; both 90%) and serum creatinine
(137+/-56 vs 139+/-44 micromol/l) after 6 months were not significantly different. However, the rate of
acute rejection episodes (defined as a rise in creatinine without other obvious cause and treated at least
with pulse steroids) was significantly reduced with MMF from 60 to 20% (P=0.0005). The resulting cost
for rejection treatment was lowered 8-fold (from sFr. 2113 to 259 averaged per patient) and the number
of transplant biopsies was lowered > 3-fold in the MMF group. The cost for the immunosuppressive
therapy was increased 1.5-fold with MMF (from sFr. 5906 to 9231 per patient for the first 6 months).
CONCLUSIONS: The change from AZA to MMF resulted in a significant reduction in early rejection
episodes, resulting in fewer diagnostic procedures and rehospitalizations. The optimal long-term regimen
in terms of patient and pharmacoeconomic benefits remains to be defined
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Reduced kidney transplant rejection rate and pharmacoeconomic
advantage of mycophenolate mofetil
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Daniel Candinas and Ulrich Binswanger
Division of Nephrology, Departments of Internal Medicine and Surgery, University Hospital, Zu¨rich, Switzerland
Abstract with MMF (from sFr. 5906 to 9231 per patient for the
first 6 months).Background. Several multinational controlled clinical
trials have shown that triple therapy immunosuppres- Conclusions. The change from AZA to MMF resulted
in a significant reduction in early rejection episodes,sive regimens which include mycophenolate mofetil
(MMF), cyclosporin A (CSA) and steroids (S) are resulting in fewer diagnostic procedures and rehospital-
izations. The optimal long-term regimen in terms ofsuperior compared with conventional regimens which
include azathioprine (AZA), CSA and S, mainly patient and pharmacoeconomic benefits remains to
be defined.because MMF reduces the rate of acute rejection
episodes in the first 6 months after kidney transplanta-
tion. Post-marketing studies are useful to evaluate the Key words: mycophenolate mofetil; pharmacoecon-
general applicability and costs of MMF-based omy; rejection; renal transplantation
immunosuppressive regimens.
Methods. Based on the excellent results of the pub-
lished controlled clinical trials, we have changed Introductionthe standard triple therapy immunosuppressive proto-
col (AZA+CSA+S) to an MMF-based regimen
Several large randomized controlled clinical trials have(MMF+CSA+S) at our centre. To analyse the impact
demonstrated that the novel immunosuppressive drugof this change in regimen, we have monitored 6-month
mycophenolate mofetil (MMF, CellCeptB) signific-patient and graft survival, rejection rate, serum creatin-
antly reduces the rate of early acute rejection episodesine and CSA levels, as well as the costs of the immuno-
after renal allograft transplantation when comparedsuppressive and anti-rejection treatments, in 40
with azathioprine (AZA) or placebo [1–4]. The pooledconsecutive renal transplant recipients (MMF group)
1-year eYcacy analysis of three clinical studies hasand have compared the data with 40 consecutive
shown that the MMF regimen reduced the rate ofpatients transplanted immediately prior to the change
biopsy-proven acute rejection episodes from 40.8% inin regimen (AZA group).
the AZA or placebo groups to 19.8% in the patientsResults. Recipient and donor characteristics were sim-
treated with 2 g of MMF per day [5]. Side eVects asilar in the AZA and MMF groups. Patient survival
well as infectious and neoplastic complications were(37/40; 92.5% in the AZA group vs 38/40; 95% in the
similar with MMF.MMF group), graft survival (36/40 vs 36/40; both
Despite the excellent results on the rate of acute90%) and serum creatinine (137±56 vs 139±44
rejection episodes, the 1-year analysis has revealed thatmmol/l ) after 6 months were not significantly diVerent.
patient survival was not better with MMF (96%)However, the rate of acute rejection episodes (defined
compared with the placebo/AZA regimens (95.3%).as a rise in creatinine without other obvious cause
The graft survival with MMF (90.4%) was also similarand treated at least with pulse steroids) was signifi-
when compared with placebo or AZA (87.6%) [5].cantly reduced with MMF from 60 to 20% (P=
Whether long-term benefits could result with the MMF0.0005). The resulting cost for rejection treatment was
regimen has not been investigated yet. The 3-yearlowered 8-fold (from sFr. 2113 to 259 averaged per
results suggest that a trend towards better graft survivalpatient) and the number of transplant biopsies was
can be obtained with MMF [6,7].lowered >3-fold in the MMF group. The cost for the
Aside from the documented advantage for theimmunosuppressive therapy was increased 1.5-fold
patient treated with MMF, another important issue is
the cost of immunosuppression. Analyses at 1 yearCorrespondence and oVprint requests to: Rudolf P. Wu¨thrich, Division
have shown that the use of MMF resulted in netof Nephrology, University Hospital, Ra¨mistrasse 100, CH-8091
Zu¨rich, Switzerland. savings despite increased total maintenance
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immunosuppression cost [8,9]. Whether MMF treat- Statistical analysis
ment is cost eVective beyond 1 year of treatment
All patient data were recorded on an Excel spreadsheet.remains to be determined.
DiVerences in categorical variables between the two groupsThe general applicability of the excellent results
were analysed with Fisher’s exact test with Yates’ continuityobtained with MMF to individual transplant centres
correction, and donor and recipient age, cold ischaemia timeneeds to be proven. By monitoring 6-month patient and HLA mismatch were compared with Student’s t-test.
and graft survival, rejection rate, transplant function Patient and graft survival and rejection rates were also
and cost, we assessed the short-term impact of a triple compared with Fisher’s exact test. Serum creatinine, CSA
therapy regimen containing MMF instead of AZA at levels and immunosuppressive doses at 3 and 6 months were
our centre. compared with Student’s t-test.
Results
Subjects and methods
Comparison of groups
Study design
A total of 80 patients were analysed in this study,
including 40 historical control patients (AZA group)We compared patient and graft survival, rejection rates,
serum creatinine and cost of immunosuppression in 40 and 40 patients treated with a regimen containing
consecutive kidney transplant patients treated with MMF MMF (MMF group). Table 1 demonstrates the base-
with a historical control group of 40 renal transplant patients line characteristics of the two groups. Both groups
treated with AZA. The standard immunosuppression (AZA were similar with respect to age, sex, height, weight,
group) was a triple therapy regimen which included the cause of end-stage renal disease, presence or absencecyclosporin A (CSA) microemulsion Sandimmune NeoralB
of panel-reactive anti-HLA antibodies (number of sens-(initial dose 8 mg/kg, then tapering to achieve CSA levels
itized patients) and previous mode of dialysis. Thebetween 150 and 250 ng/ml ), prednisone (initial dose
number of patients who were retransplants was higher1 mg/kg/day; then tapering to a dose of 10 mg/day within 6
in the AZA group (5 vs 1; P=0.2).months after transplantation) and AZA (1–1.5 mg/kg/day).
Sandimmune was given intravenously at 3 mg/kg/day for the The donor characteristics were also quite similar
first 24 h. Sensitized patients, retransplants, patients with (Table 2). More recipients in the MMF group dis-
delayed graft function or patients receiving a transplant with played delayed graft function (25% vs 12.5%; P=0.25)
donor age >65 received a 7-day course of Anti-Thymocyte despite comparable cold ischaemia times of the grafts,
Globulin (ATG) (Fresenius, 3 mg/kg/day i.v.) for induction reflecting perhaps the slightly higher age of the donors
treatment with delayed introduction of CSA. MMF was used in the MMF group. The number of HLA-A, -B andat a dose of 2×1 g/day instead of AZA in the MMF group.
-DR mismatches was also not diVerent between donors
and recipients, and the cytomegalovirus (CMV ) con-
stellations between donor and recipients were alsoOutcome measurements
similar.
Donor and recipient characteristics were compared and
examined for statistically significant diVerences. Patient and EYcacy
graft survival rates were then determined after 6 months in
Table 3 shows that the 6-month patient survival ratesboth groups. Episodes of acute rejection—defined as a rise
in serum creatinine not due to obstruction, hypovolaemia, were similar in both treatment groups (95% in the
cyclosporin toxicity or any other obvious cause and treated MMF group vs 92.5% in the AZA group). Likewise,
at least with pulse steroids (500–1000 mg for 3–5 days)— the graft survival rates were not diVerent (90% in both
were recorded in both groups and the results of any biopsies groups). The causes of death and graft failure are also
were also checked. Serum creatinine, immunosuppression reported in Table 3. Due to the low number of events,
and cyclosporin levels were also recorded at 3 and 6 months a significant diVerence cannot be excluded.and compared.
The systematic use of MMF instead of AZA reducedWe also analysed the cost of the baseline immunosuppres-
the incidence of clinically diagnosed acute rejection epis-sion and the costs of induction and rejection treatments in
odes in the first 6 months after transplantation fromboth groups. The cost of the baseline immunosuppression
60% to 20% (P=0.0005). Table 4 demonstrates thatwas estimated in Swiss Francs based on average doses used
of Sandimmune NeoralB (300 mg/day), AZA (75 mg/day), steroid-sensitive episodes were the most frequent type of
MMF (2 g/day) and prednisone (20 mg/day) in the first 6 acute rejection, and their number was markedly reduced
months after transplantation. Costs of the induction treat- in the MMF group. The number of ATG or OKT3
ments with ATG (7×200 mg), and costs for rejection treat- treatments for steroid-resistant rejection was also
ments were calculated based on average treatments with reduced in the MMF group (due in part also to the
pulse steroids (5×1 g i.v. methylprednisolone), ATG recent availability in 1997 of FK506 to treat steroid-Fresenius (7×200 mg) or OKT3 (7×5 mg). In addition, we
resistant rejection episodes). Table 4 also shows that therecorded the number of transplant biopsies (reflecting the
mean time to rejection was similar in both groups.diagnostic activity due to presumed rejection) and examined
Table 5 demonstrates that significantly fewer dia-the number of prolonged hospitalizations and rehospitaliza-
gnostic transplant biopsies were needed in the MMFtions for treatment of rejection (reflecting supplemental hos-
pital costs due to rejection). group compared with the AZA group (8 vs 27).
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Table 1. Baseline characteristics of renal allograft recipients
Characteristic AZA group (n=40) MMF group (n=40)
Inclusion period 8/1996–1/1997 (6 months) 2/1997–11/1997 (10 months)
Age (years) 46.6±11.8 (24–68) 47.2±13.0 (18–66)
Gender (M5F) 28512 25515
Height (cm) 171.5±9.7 169.2±9.1
Weight (kg) 70.2±12.4 69.8±11.1
Cause of renal failure
Glomerulonephritis 12 18
Chronic TIN 7 6
Diabetes 2 2
Hereditary or PKD 9 5
Hypertension 2 1
Other 8 8
Type of transplant
1. CAD 33 35
2. CAD 5 1
1. LRD 2 4
No. sensitized 3/40 4/40
Mode of dialysis
HD 31 30
CAPD 8 9
None 1 1
Baseline recipient characteristics were recorded and analysed for diVerences. Averaged data represent mean±SD. The recipient age range
is indicated in parentheses. No statistically significant diVerences were detected between the two groups.
CAD, cadaveric; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis; LRD, live related donor; PKD, polycystic kidney
disease; TIN; tubulointestinal nephritis.
Table 2. Baseline donor characteristics
AZA MMF
Age (years) 37.6±14.5 (13–66) 44.1±15.4 (18–69)
Gender (M5F) 22518 29511
Cold ischaemia time (min) 772±359 694±341
(60–1815) (90–1340)
Delayed graft function 5/40 10/40
HLA mismatch 3.6±1.0 3.7±1.2
CMV (D/R)
−/− 7 8
−/+ 5 8
+/+ 20 16
+/− 8 8
Baseline donor characteristics were recorded and analysed for diVerences. Averaged data represent mean±SD. The donor age and cold
ischaemia time ranges are indicated in parentheses. No statistically significant diVerences were detected between the two groups.
Table 3. Patient and graft survival rates after 6 months and causes of death and graft failure
AZA MMF
Patient survival 37/40 (92.5%) 38/40 (95%)
Graft survival 36/40 (90%) 36/40 (90%)
Causes of death Carcinoma of pancreas Sepsis, multiorgan failure
Encephalitis Perforation of caecum, sepsis
Fulminant hepatitis
Causes of graft failure:
Death with functioning graft 3 2
Rejection 1 1
Technical – 1
Patient and graft survival rates and the causes of death and graft failure are reported for both groups.
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Table 4. Rejection episodes and therapy adverse events were recorded in either group that could
be ascribed to either the immunosuppressive regimen
AZA MMF or to a single immunosuppressive drug. The occurrence
and the course of CMV infections was similar in both
Rejection rate 60% 20%* groups: five patients developed non-invasive CMV
Patients with disease in each group. There were no Pneumocystis
no rejection 16/40 32/40 carinii infections in both groups. The MMF regimen
1 rejection 13/40 5/40
was well tolerated, and gastrointestinal side eVects2 rejections 7/40 2/40
were rare. The MMF dosage had to be reduced tempor-3 or more rejections 4/40 1/40
No. of rejection treatments applied arily in six patients due to CMV infection (n=4),
Steroid bolus 27 7 leukopenia (n=1) or anaemia (n=1).
ATG or ATGAM 9 0
FK506 0 3
OKT3 2 1 Costs
Time to rejection (days) 12.3±8.2 10.0±4.1
Table 7 indicates the cost of the two regimens averaged
per patient for the 6-month period. Whereas theThe number of patients with none, 1, 2 and 3 or more rejection
episodes in the first 6 months after transplantation is reported. immunosuppression therapy was 1.8-fold more expens-
Furthermore, the number of treatments with methylprednisolone ive with MMF, 8-fold greater costs arose from the
bolus, ATG or ATGAM, FK506 (‘rescue’) or OKT3 is indicated, treatment of the more frequent rejection episodes indemonstrating that MMF markedly reduces the incidence of acute
the AZA group. Due to the higher number of inductionrejections and the number of treatments. No change in time to
treatments in the MMF group (23 vs 16), morerejection is seen.
*P<0.0005. expenses resulted from ATG induction treatments in
the MMF group. The total estimated costs for
immunosuppressive drugs was 24% higher in theTable 5. Diagnostic biopsies and rejection type (BanV )
patients in the MMF group in the first 6 months.
Important additional savings could be documentedAZA MMF
in the MMF group, although the amount of these
costs could not be estimated. For example, 3-fold lessNormal 7 3
diagnostic biopsies were required in the MMF groupNon-specific or borderline 10 3
BanV grade I 9 1 (Table 5). Transplant biopsies can be regarded as an
BanV grade IIa 0 0 indicator of diagnostic activities around a rejection
BanV grade IIb 1 1
episode, and certainly there were also fewer laboratoryTotal no. of biopsies 27 8
tests and radiological procedures such as transplant
ultrasound examinations in the MMF group. In addi-The number of diagnostic biopsies in the first 6 months after
tion, in the MMF group, there were also fewer pro-transplantation and the BanV grading is reported. Significantly fewer
biopsies were performed in the MMF group. longed hospitalizations and rehospitalizations for the
treatment of steroid-resistant rejection episodes, which
generally require central line placement and i.v. ATGClassification of these biopsies according to the BanV
treatment (data not shown).scheme [10] revealed that the histopathological lesions
were similar in both groups, with more than half of
the biopsies showing a normal histology or non-specific
Discussionchanges.
The serum creatinine values at 6 months were also
This study reports on the successful use of MMFnot diVerent in the two groups (137±56 mmol/l in the
instead of AZA after renal allograft transplantation atAZA group vs 139±44 in the MMF group). Table 6
a single centre. The change from AZA to MMFshows that the average daily doses of prednisone and
decreased the 6-month rejection rate 3-fold from 60 tocyclosporin did not diVer at any time between the two
20%. Our data are in agreement with the previouslygroups, nor was there a significant diVerence in the
reported international trials [1–4] and demonstratecyclosporin levels. More patients were treated with
that an individual centre can successfully reduce theATG induction in the MMF group (57.5% vs 40%;
rate of acute rejection episodes in renal transplantP=0.18). This could have influenced the rejection
patients when changing from an AZA-containing torate slightly.
an MMF-containing triple therapy regimen. The addi-
tional benefits of this treatment strategy are a lowerSide eVects requirement for diagnostic procedures and fewer rehos-
pitalizations for treatment of steroid-resistant rejectionTreatment failures were low and comparable in both
groups. The number of patients with functioning episodes.
Our study is the first to document enhanced eVect-graft at 6 months on the initial triple regimen
(MMF+prednisone+CSA) was 32/36, compared with iveness of MMF compared with AZA in Sandimmune
NeoralB (CSA microemulsion)-treated patients; the35/36 with the AZA+prednisone+CSA regimen.
During the 6-month observation period, no serious previously published studies were all performed with
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Table 6. Comparison of the immunosuppressive regimens
AZA MMF
Initial regimen
Sandimmune i.v. 3 mg/kg/day 3 mg/kg/day
Neoral p.o. 8 mg/kg/day 8 mg/kg/day
Prednisone 1 mg/kg/day 1 mg/kg/day
MMF – 2000 mg/day
AZA dose 1–1.5 mg/kg/day –
ATG induction 16/40 (40%) 23/40 (57.5%)
Maintenance regimen At 3 months At 6 months At 3 months At 6 months
Neoral p.o. (mg/day) 271±82 253±74 261±75 247±69
Prednisone (mg/day) 19±5 10±3 16±5 10±0
MMF (mg/day) – – 1742±435 1950±201
AZA (mg/day) 74±17 72±19 – –
CSA level (ng/ml ) 202±51 198±47 216±64 207±66
The initial regimen, the use of ATG induction therapy with ATG Fresenius and the mean±SD dosages of cyclosporin, prednisone,
azathioprine and mycophenolate mofetil are reported at 3 and 6 months for both groups.
Table 7. Estimated cost of immunosuppression tocol to an MMF-based protocol, the 6-month rejec-
tion rate at our centre was reduced from 60 to 20%.
AZA MMF With the approach of monitoring patient data over 6
months and comparing with a historical control, we
Immunosuppression 5906 9231 were able to detect the beneficial eVect of MMF on
Induction with ATG 2536 3646 the rejection rate very rapidly. The pharmacoeconomic
Rejection treatment 2113 259 advantage of using MMF for 6 months is reflected in
Total cost 10 555 13 136
the reduced number of diagnostic procedures and
treatment costs for rejection episodes. Whether treat-
Cost of immunosuppression, induction and rejection treatments were
ment with MMF beyond 6 months is necessary andaveraged per patient for the 6-month period and are indicated in
cost eVective remains to be determined.Swiss Francs. Calculations were based on an average daily use of
2×150 mg of CSA, 75 mg of AZA or 2×1000 mg of MMF, and
Acknowledgements. Part of these data was presented at the 3rd20 mg of prednisone. Average induction therapy was with ATG
International Conference on New Trends in Clinical and(200 mg/day for 7 days), and rejection treatments were with methyl-
Experimental Immunosuppression in Geneva in February 1998.prednisolone pulses (1000 mg/day for 5 days), ATG (200 mg/day
for 7 days) or OKT3 (5 mg/day for 7 days).
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